Selling pressure pushes Hims & Hers Health stock lower in today's trading

Traders Union
All News
Financial News
Hims & hers slides 2.35% today

Highlights

Hims & Hers Health reported a $92.1 million net loss and missed EPS estimates as it pivoted to branded GLP-1 therapies with Novo Nordisk.
First-quarter revenue reached $608.1 million, including $33 million in restructuring charges, and over 125,000 Wegovy shipments were completed in six weeks.
Shares remain under sustained downward pressure, trading near oversold technical levels with an expected five-day price range of $23.12 to $24.24.

Broader selling persists amid strategic pivot and partnership news

Hims & Hers Health reported a net loss of $92.1 million for the first quarter as it shifted its strategy toward branded GLP-1 therapies, including a new partnership with Novo Nordisk on Wegovy. Loss per share was $0.40, missing consensus estimates, with revenue totaling $608.1 million and including approximately $33 million in restructuring charges related to this pivot. Over 125,000 Wegovy shipments were fulfilled within six weeks of the partnership, and strong patient feedback on GLP-1 pill affordability and efficacy was noted, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees clear signs of technical and fundamental weakness in Hims & Hers Health. With the stock trading under every major moving average and repeatedly failing to hold support, he observes sellers firmly in control. Recent net losses, a missed earnings estimate, and heavy restructuring charges reinforce downward pressure. Short-term indicators may show oversold signals, but Kharitonov views these as insufficient for a sustainable reversal in the absence of improved fundamentals. "Current momentum and persistent losses suggest that HIMS remains at risk of drifting lower unless meaningful catalysts emerge," he warns.

Viktoras Karapetjanc, expert at Traders Union, highlights the strategic pivot toward branded GLP-1 therapies and the partnership with Novo Nordisk as major opportunities for Hims & Hers Health. He remains confident about the long-term outlook and notes strong demand for the Wegovy shipments. Despite current pressure, Karapetjanc asserts that positive patient feedback demonstrates underlying market appetite. "The bullish structure remains intact on a fundamental level — further growth is anticipated if execution continues and the market stabilizes," he states.

Parshwa Turakhiya, analyst, focuses on the tug-of-war between negative sentiment and emerging technical setups. Multiple daily indicators confirm deeply oversold conditions, yet strong bearish momentum persists. Turakhiya sees a potential short-term bounce if buyers defend the $23.12 level, but is cautious about follow-through. "If volatility spikes and the price rebounds off key support, nimble traders could catch a sentiment-driven move," the analyst concludes.

Oversold conditions deepen as bears dominate intraday momentum

Momentum indicators show mixed signals: MACD suggests a strong upward reversal bias on the daily timeframe while the Average Directional Index (ADX) signals a potential for strengthening trends. Multiple oscillators, including the Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI), indicate oversold conditions. Bull/Bear Power (BBP) is deeply negative, confirming that sellers are firmly in control intraday and also signaling an oversold setup. The daily profile reveals a downside gap of approximately $0.18 at the open, and the price is now near the low of the session, having slipped 2.35% from the previous close. Intraday volatility stands at 1.89%, and the session shows continued pressure from sellers shortly after the open. The divergence between oversold oscillators and the strong bearish momentum suggests that although sellers dominate, the stock is approaching technically stretched levels.

Earlier, analysts noted that Hims & Hers Health faced ongoing volatility and downside risk as technical and operational pressures limited any sustained upward momentum. The latest session's deepening oversold conditions and persistent selling pressure suggest that while the stock is technically stretched, traders should monitor for a potential reversal if resistance at $24.24 is breached or prepare for further weakness should the $23.12 floor give way.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.